AU2010325980B2 - Proline derivatives - Google Patents

Proline derivatives Download PDF

Info

Publication number
AU2010325980B2
AU2010325980B2 AU2010325980A AU2010325980A AU2010325980B2 AU 2010325980 B2 AU2010325980 B2 AU 2010325980B2 AU 2010325980 A AU2010325980 A AU 2010325980A AU 2010325980 A AU2010325980 A AU 2010325980A AU 2010325980 B2 AU2010325980 B2 AU 2010325980B2
Authority
AU
Australia
Prior art keywords
compound
compounds
mmol
independently
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010325980A
Other languages
English (en)
Other versions
AU2010325980A1 (en
Inventor
Yu-Sheng Chao
Jyh-Haur Chern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of AU2010325980A1 publication Critical patent/AU2010325980A1/en
Application granted granted Critical
Publication of AU2010325980B2 publication Critical patent/AU2010325980B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2010325980A 2009-12-04 2010-12-02 Proline derivatives Ceased AU2010325980B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26658409P 2009-12-04 2009-12-04
US61/266,584 2009-12-04
PCT/US2010/058672 WO2011068941A2 (en) 2009-12-04 2010-12-02 Proline derivatives

Publications (2)

Publication Number Publication Date
AU2010325980A1 AU2010325980A1 (en) 2012-06-14
AU2010325980B2 true AU2010325980B2 (en) 2016-04-07

Family

ID=44082623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010325980A Ceased AU2010325980B2 (en) 2009-12-04 2010-12-02 Proline derivatives

Country Status (10)

Country Link
US (1) US8415482B2 (enExample)
EP (1) EP2507232B1 (enExample)
JP (1) JP5753185B2 (enExample)
KR (1) KR101768946B1 (enExample)
CN (1) CN102482269B (enExample)
AU (1) AU2010325980B2 (enExample)
CA (1) CA2781140C (enExample)
MY (1) MY179840A (enExample)
TW (1) TWI429645B (enExample)
WO (1) WO2011068941A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010120935A1 (en) * 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
EP2853531A3 (en) 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20140127158A1 (en) * 2012-11-08 2014-05-08 National Health Research Institute Combination therapy for hepatitis c virus infection
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104774194B (zh) * 2014-01-09 2018-01-30 正大天晴药业集团股份有限公司 氘代的丙型肝炎病毒抑制剂
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
IL310924A (en) 2021-08-25 2024-04-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof
CN113861061A (zh) * 2021-10-25 2021-12-31 成都市科隆化学品有限公司 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法
WO2024089272A1 (en) * 2022-10-28 2024-05-02 Institut National De La Sante Et De La Recherche Medicale New inhibitors of phosphatidylinositol 3-kinase
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043545A1 (en) * 2001-11-02 2005-02-24 Gianpalol Bravi 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
SG176015A1 (en) * 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
AU2010325980A1 (en) 2012-06-14
US20110136799A1 (en) 2011-06-09
KR20120102690A (ko) 2012-09-18
CN102482269B (zh) 2015-07-29
CA2781140C (en) 2017-10-24
MY179840A (en) 2020-11-18
HK1171439A1 (zh) 2013-03-28
WO2011068941A3 (en) 2011-11-17
JP5753185B2 (ja) 2015-07-22
JP2013512915A (ja) 2013-04-18
US8415482B2 (en) 2013-04-09
CN102482269A (zh) 2012-05-30
EP2507232A2 (en) 2012-10-10
EP2507232A4 (en) 2013-12-18
KR101768946B1 (ko) 2017-08-17
CA2781140A1 (en) 2011-06-09
TW201120035A (en) 2011-06-16
EP2507232B1 (en) 2019-03-20
WO2011068941A2 (en) 2011-06-09
TWI429645B (en) 2014-03-11

Similar Documents

Publication Publication Date Title
AU2010325980A1 (en) Proline derivatives
KR101578954B1 (ko) 이미다졸카르보닐 화합물
AU2001294196B2 (en) Nitrogenous five-membered ring compounds
CA2483998C (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
KR102151288B1 (ko) [오르토 바이 (헤테로 )아릴]-[2-(메타 바이 (헤테로 )아릴)-피롤리딘-1-일]-메타논 유도체인 오렉신 수용체 안타고니스트
DK2784075T3 (en) Hepatitis C viral inhibitors
WO2023043816A1 (en) Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2010017401A1 (en) Bi-1h-benzimidazoles as hepatitis c virus inhibitors
AU2007322608A1 (en) Heteromonocyclic compound and use thereof
WO2011091446A1 (en) Chemical compounds
NZ588266A (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
CA2633569A1 (en) N-(5-membered heteroaromatic ring)-amido anti-viral compounds
WO2008005368A2 (en) Piperazines as p2x7 antagonists
EP1983992A2 (en) 2-imino-benzimidazoles
WO2006073167A1 (ja) ピロリジン誘導体
JP2011026305A (ja) イミダゾールカルボニル化合物を含有する医薬組成物
WO2009111239A2 (en) Pyrrolidine derivatives
EP2178863A1 (en) Process for synthesizing compounds useful for treating hepatitis c
WO2005103012A1 (ja) ヒドラジノ複素環ニトリル化合物およびその用途
CA2486933A1 (en) Tetrahydropyran derivative
HK1171439B (en) Proline derivatives
OA22136A (en) Pyrrole compounds.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired